

# Carolina Solis-Herrera

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5370689/publications.pdf>

Version: 2024-02-01

21  
papers

1,466  
citations

687363

13  
h-index

713466

21  
g-index

21  
all docs

21  
docs citations

21  
times ranked

2200  
citing authors

#	ARTICLE	IF	CITATIONS
1	Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. <i>Journal of Clinical Investigation</i> , 2014, 124, 509-514.	8.2	661
2	Assessment of Pancreatic $\beta$ -Cell Function: Review of Methods and Clinical Applications. <i>Current Diabetes Reviews</i> , 2014, 10, 2-42.	1.3	179
3	Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2016, 39, 2036-2041.	8.6	155
4	Dapagliflozin Lowers Plasma Glucose Concentration and Improves $\beta$ -Cell Function. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 1927-1932.	3.6	133
5	Empagliflozin Treatment Is Associated With Improved $\beta$ -Cell Function in Type 2 Diabetes Mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 1402-1407.	3.6	63
6	Mechanisms of Glucose Lowering of Dipeptidyl Peptidase-4 Inhibitor Sitagliptin When Used Alone or With Metformin in Type 2 Diabetes. <i>Diabetes Care</i> , 2013, 36, 2756-2762.	8.6	52
7	Pioglitazone Improves Left Ventricular Diastolic Function in Subjects With Diabetes. <i>Diabetes Care</i> , 2017, 40, 1530-1536.	8.6	45
8	Therapeutic Manipulation of Myocardial Metabolism. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2022-2039.	2.8	40
9	Effect of Dapagliflozin With and Without Acipimox on Insulin Sensitivity and Insulin Secretion in T2DM Males. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 1249-1256.	3.6	30
10	Increase in endogenous glucose production with SGLT2 inhibition is attenuated in individuals who underwent kidney transplantation and bilateral native nephrectomy. <i>Diabetologia</i> , 2020, 63, 2423-2433.	6.3	17
11	Nephropathy in Youth and Young Adults with Type 2 Diabetes. <i>Current Diabetes Reports</i> , 2014, 14, 456.	4.2	16
12	Increase in Endogenous Glucose Production With SGLT2 Inhibition Is Unchanged by Renal Denervation and Correlates Strongly With the Increase in Urinary Glucose Excretion. <i>Diabetes Care</i> , 2020, 43, 1065-1069.	8.6	15
13	Effect of Mild Physiologic Hyperglycemia on Insulin Secretion, Insulin Clearance, and Insulin Sensitivity in Healthy Glucose-Tolerant Subjects. <i>Diabetes</i> , 2021, 70, 204-213.	0.6	15
14	GLP-1 Receptor Agonists. <i>The Diabetes Educator</i> , 2015, 41, 32S-46S.	2.5	11
15	Inhibition of renal glucose reabsorption as a novel treatment for diabetes patients. <i>Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia</i> , 2014, 36, 80-92.	0.9	11
16	Prevalence and Heritability of Clusters for Diagnostic Components of Metabolic Syndrome: The Oman Family Study. <i>Metabolic Syndrome and Related Disorders</i> , 2008, 6, 129-135.	1.3	8
17	A new perspective on lowering CV risk from hypoglycaemia. <i>European Heart Journal</i> , 2020, 41, 218-220.	2.2	6
18	Dapagliflozin Impairs the Suppression of Endogenous Glucose Production in Type 2 Diabetes Following Oral Glucose. <i>Diabetes Care</i> , 2022, 45, 1372-1380.	8.6	4

#	ARTICLE	IF	CITATIONS
19	Clinical Parameters, Fuel Oxidation, and Glucose Kinetics in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus Saxagliptin. <i>Diabetes Care</i> , 2020, 43, 2519-2527.	8.6	3
20	Cardioprotective Effects of Pioglitazone in Type 2 Diabetes. <i>Diabetes Spectrum</i> , 2021, 34, 243-247.	1.0	1
21	Antihyperglycemic Algorithms for Type 2 Diabetes: Focus on Nonglycemic Outcomes. <i>Diabetes Spectrum</i> , 2021, 34, 248-256.	1.0	1